| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
|
Grünwald, Viktor
|
|
2012
|
48 |
3 |
p. 324-332
9 p.
|
artikel
|
| 2 |
A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study
|
Geoerger, Birgit
|
|
2012
|
48 |
3 |
p. 289-296
8 p.
|
artikel
|
| 3 |
Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience
|
Lafay-Cousin, L.
|
|
2012
|
48 |
3 |
p. 353-359
7 p.
|
artikel
|
| 4 |
Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]
|
Clarke, Stephen J.
|
|
2012
|
48 |
3 |
p. 407-
1 p.
|
artikel
|
| 5 |
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
|
Calvo, E.
|
|
2012
|
48 |
3 |
p. 333-339
7 p.
|
artikel
|
| 6 |
Evolution of requests to hasten death among patients managed by palliative care teams in France: A multicentre cross-sectional survey (DemandE)
|
Ferrand, Edouard
|
|
2012
|
48 |
3 |
p. 368-376
9 p.
|
artikel
|
| 7 |
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
|
Cella, D.
|
|
2012
|
48 |
3 |
p. 311-323
13 p.
|
artikel
|
| 8 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
|
Pesce, Gianfranco A.
|
|
2012
|
48 |
3 |
p. 377-384
8 p.
|
artikel
|
| 9 |
Physical activity in a German breast cancer patient cohort: One-year trends and characteristics associated with change in activity level
|
Huy, Christina
|
|
2012
|
48 |
3 |
p. 297-304
8 p.
|
artikel
|
| 10 |
Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
|
Amir, Eitan
|
|
2012
|
48 |
3 |
p. 385-388
4 p.
|
artikel
|
| 11 |
Targeting Raf/MEK/ERK pathway in pituitary adenomas
|
Suojun, Zhang
|
|
2012
|
48 |
3 |
p. 389-395
7 p.
|
artikel
|
| 12 |
Tetraploidy in BRCA2 breast tumours
|
Jonsdottir, Asta Bjork
|
|
2012
|
48 |
3 |
p. 305-310
6 p.
|
artikel
|
| 13 |
The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy
|
Hernlund, Emma
|
|
2012
|
48 |
3 |
p. 396-406
11 p.
|
artikel
|
| 14 |
The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL
|
Giebel, Sebastian
|
|
2012
|
48 |
3 |
p. 360-367
8 p.
|
artikel
|
| 15 |
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
|
Gomez-Fernandez, Cristina
|
|
2012
|
48 |
3 |
p. 340-346
7 p.
|
artikel
|
| 16 |
Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: A national multicentre study
|
Riber-Hansen, Rikke
|
|
2012
|
48 |
3 |
p. 347-352
6 p.
|
artikel
|
Tijdschrift beschrijving